Drug profile · INN
solriamfetol hydrochloride
SUNOSI
solriamfetol hydrochloride (SUNOSI) is a unknown. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — solriamfetol hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 0
- Data quality
- 0.89
Quick answer
solriamfetol hydrochloride (SUNOSI) is a unknown. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related patents
-
US 12390419
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 12384743
Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
granted -
US 12318362
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12268693
Pharmaceutical compositions comprising a tolfenamic acid
granted -
US 12263145
Methods of administering solriamfetol to lactating women
granted -
US 12194016
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 12102609
Methods of administering solriamfetol to lactating women
granted -
US 12090126
Methods of administering solriamfetol to lactating women
granted -
US 12064411
Methods of administering solriamfetol to lactating women
granted -
US 12036194
Methods of administering solriamfetol to lactating women
granted -
US 12005036
Methods of administering solriamfetol to lactating women
granted -
US 11998639
Formulations of (R)-2-amino-3-phenylpropyl carbamate
granted -
US 11986454
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11986455
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11969404
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11872203
Methods of administering solriamfetol to lactating women
granted -
US 11872204
Methods of administering solriamfetol to lactating women
granted -
US 11865098
Methods and compositions for treating excessive sleepiness
granted -
US 11857528
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11850227
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted
Frequently asked questions
What is solriamfetol hydrochloride?
solriamfetol hydrochloride (SUNOSI) is a unknown. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for solriamfetol hydrochloride?
SUNOSI is a marketed brand name for solriamfetol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of solriamfetol hydrochloride?
solriamfetol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.